The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder
Ying Jiang, Yucai Qu, Lingyi Shi, Mengmeng Ou, Zhiqiang Du, Zhenhe Zhou, Hongliang Zhou, Haohao Zhu · 2024
Read The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder by Ying Jiang, Yucai Qu, Lingyi Shi, Mengmeng Ou, Zhiqiang Du, Zhenhe Zhou, Hongliang Zhou, Haohao Zhu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11655517.txt.
Description
Ying Jiang and co-authors studied why antidepressants help some patients and not others in 2024. The drugs in view were SSRIs, a front-line class for major depression. Gut microbes steer body chemistry in ways that reach the brain, and their metabolic output may tilt a drug's effect.
The team profiled gut microbes and blood metabolites in 126 patients before and after SSRI care. Patients were split into responders and non-responders by a standard depression score. Links between microbe makeup and drug response were then modeled, toward a test that forecasts who will benefit. Such a test could spare months of trial and error.
Catalog record
| CREATOR | Ying Jiang, Yucai Qu, Lingyi Shi, Mengmeng Ou, Zhiqiang Du, Zhenhe Zhou, Hongliang Zhou, Haohao Zhu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |